US drugs giant finally seals £32bn takeover of Shire
Friday 18 July 2014
The FTSE 100 big-pharma player Shire celebrated a £32bn takeover by US suitor AbbVie with record results as the two companies beat a Takeover Panel deadline to agree a firm offer.
The UK firm unveiled a 22 per cent rise in quarterly revenues to a record $1.5bn (£877m) and upgraded profit targets for the year as its chief executive Flemming Ornskov called the performance “a testament to the value AbbVie sees in our company”.
AbbVie’s fifth offer for Shire – worth £53.19 in cash and shares – adds to a clutch of major deals in the sector this year. The firm has succeeded in landing a UK target where larger rival Pfizer failed after an unsuccessful and controversial bid for AstraZeneca.
The US company will also pay a break fee of 3 per cent of the value of the offer – worth £960m – to Shire if the deal fails to go through, according to the offer document.
The two companies have been locked in talks in New York over the fine print of the deal, which AbbVie is pushing for to broaden its portfolio and move its tax base to the UK. This would cut its tax rate from 22 per cent to around 13 per cent under a so-called “inversion” deal.
Shire’s chair Susan Kilsby is believed to have been pushing for the big break fee due to increasing political risks around such tax deals as a US Senator has put forward legislation to make them more difficult, potentially reducing AbbVie’s tax benefits.
But AbbVie has also coveted Shire to reduce its reliance on rheumatoid arthritis treatment Humira, which soon loses patent protection. Shire’s best-known product – hyperactivity drug Vyvanse – saw sales rose 20 per cent to $360m over the quarter, but the company also reported strong sales of treatments for rare diseases from the ViroPharma business it bought for $4.2bn last year.
Sales of Cinryze, ViroPharma’s treatment for a rare blood disorder which causes swelling, were up 37 per cent year on year to $129.9m.
Shire was founded in 1986 by a group of five scientists. It is listed on the London Stock Exchange, has its tax base in Dublin but sells most of its products in North America.
AbbVie’s pursuit of Shire started in early May, just as AstraZeneca was fighting off Pfizer. The US firm was formed last year when Abbott Laboratories split into two companies, a medical products business which retained the Abbott name and a pharmaceuticals firm which became AbbVie.
- 1 Barbarians vs Samoa interrupted by sprinklers as fans criticise lack of Wi-Fi and poor seating at West Ham's Olympic Stadium
- 2 Watch the Supermoon live: How to see the brightest Moon of the year tonight
- 3 Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
- 4 Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
- 5 David De Gea to Real Madrid: Real finally get their man with £29m bid for Manchester United goalkeeper
Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
Watch the Supermoon live: How to see the brightest Moon of the year tonight
Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Turkey duped the US, and Isis reaps rewards
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
Theresa May says migrants should be banned from entering the UK unless they have jobs lined up
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...